**现报告由 ××××公司申办的 ××××（报告周期，例如：2020年5月）收到的关于 ××××（试验药物名称）的SUSAR报告，共计 份。涉及该药物的所有注册临床试验目前总共入组 例受试者。以下为本次报告的可疑且非预期严重不良反应（SUSAR）行列表。**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **可疑且非预期严重不良反应（SUSAR）行列表** | | | | | | | | | | | | | | |
| **序号** | **方案编号** | **受试者编号** | **性别** | **年龄** | **适应症** | **报告类型** | **给药开始日期** | **事件发生日期** | **安全性事件医学术语** | **研究者的相关性评价** | **申办者的相关性评价** | **对试验药物采取的措施** | **安全性事件转归** | **同类事件既往发生的例数** |
| 1 | 00000 | 001 | 男/女 | n岁 | 2型糖尿病 | 首次/随访/总结 | 2020/01/01 | 2020/06/10 | 急性肝功能衰竭 | 有关/无关 | 有关/无关 | 继续用药/暂停用药/永久停药等 | 好转/缓解/痊愈/死亡等 | n例/无 |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

备注：1.列表顺序应按事件发生日期排列；2.同一例事件应按报告类型（首次-随访-总结）的顺序排列在一起；3.每一页都应包含表头。